Phase 3 Readout

LONA: Phase 3 Topline: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of

Name: Phase 3 Topline: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of
Start: 2028-04-01
End: 2028-04-01

April 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: April 1, 2028
Company: LeonaBio, Inc. (LONA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of

April 1, 2028

LONA overview →

Company: LeonaBio, Inc. (LONA)
Indication: Metastatic Breast Cancer